SLC5A2 and diabetic kidney disease: Despite the advances in renoprotective therapies, such as renin-angiotensin system blockade and sodium-glucose cotransporter-2 inhibitors1,2, the prevalence of diabetic kidney disease (DKD) and resources spent on healthcare due to DKD are increasing globally in patients with type 2 diabetes mellitus.